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Abstract
Heterologous expression platforms of biopharmaceutical proteins have been significantly improved over the last decade.
Further improvement can be established by examining the intrinsic properties of proteins. Interleukin-10 (IL-10) is an anti-
inflammatory cytokine with a short half-life that plays an important role in re-establishing immune homeostasis. This
homodimeric protein of 36 kDa has significant therapeutic potential to treat inflammatory and autoimmune diseases. In this
study we show that the major production bottleneck of human IL-10 is not protein instability as previously suggested, but
extensive multimerisation due to its intrinsic 3D domain swapping characteristic. Extensive multimerisation of human IL-10
could be visualised as granules in planta. On the other hand, mouse IL-10 hardly multimerised, which could be largely
attributed to its glycosylation. By introducing a short glycine-serine-linker between the fourth and fifth alpha helix of human
IL-10 a stable monomeric form of IL-10 (hIL-10mono) was created that no longer multimerised and increased yield up to 20-
fold. However, hIL-10mono no longer had the ability to reduce pro-inflammatory cytokine secretion from lipopolysaccharide-
stimulated macrophages. Forcing dimerisation restored biological activity. This was achieved by fusing human IL-10mono to
the C-terminal end of constant domains 2 and 3 of human immunoglobulin A (Fca), a natural dimer. Stable dimeric forms of
IL-10, like Fca-IL-10, may not only be a better format for improved production, but also a more suitable format for medical
applications.
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Introduction
Recombinant DNA technology has revolutionized the produc-
tion and application of pharmaceutical proteins. Current heterol-
ogous production hosts include bacteria, yeasts, insect and
mammalian cells, and, more recently, plants. Most expression
systems have been rapidly improved in terms of yield and cost
efficiency in the last decades. However, these advances have
mainly been achieved with antibodies and hormones, which are
relatively stable proteins. Recently more attention in optimizing
the production of biopharmaceutical proteins is directed to their
intrinsic properties that result of post-translational modifications
and folding processes. Improved insight in these processes may
increase the yield of still poorly expressed proteins.
Many cytokines have a promising therapeutic potential.
However, several cytokine families show a short half-life in vivo
and are poorly expressed in heterologous hosts. Human interleu-
kin-10 (IL-10) is such a cytokine that may be used for treatment of
many inflammatory and autoimmune diseases due to its immu-
nosuppressive properties [1,2]. Generally, IL-10 facilitates the
return of the immune system to homeostasis after clearance of
antigen and plays an important role in conferring oral tolerance. It
exerts its function through reduction of the activity of macro-
phages, inhibition of antigen presentation by dendritic cells and
inhibition of the production of pro-inflammatory cytokines by
antigen presenting cells and T lymphocytes [3–6]. The human IL-
10 gene encodes a 178 amino acid protein including a N-terminal
signal peptide for secretion. An IL-10 monomer consists of six
alpha helices (A–F) with two internal disulphide bridges (Cys30-
Cys126 and Cys80-Cys132). Two monomers are stabilized into a
biologically active dimer by exchanging their C-terminal domains
composed of the helices E and F, a process called 3D domain
swapping [7–9].
Human interleukin-10 has previously been produced in
bacterial systems for medical purposes [10,11], and in insect and
mammalian cells for research purposes. The use of plants as a
production platform for IL-10 provides a cheap alternative
compared to bacterial, insect and mammalian expression systems.
As plants are eukaryotes they can correctly fold and assemble
proteins, and are able to perform complex post-translational
processes, such as glycosylation. Plants as production hosts for IL-
10 offer an extra advantage as they have a low risk of
contamination with human pathogens, especially relevant when
producing immunosuppressive molecules for medical application.
Human IL-10 was produced for the first time in planta by stable
transformation of a low-alkaloid Nicotiana tabacum variety [12].
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High transcript levels were contrasted by low protein levels with a
maximum of 0.000069% of total soluble protein (TSP). Biological
activity of plant-derived human IL-10 was shown in vitro and in vivo
without the need for purification [12,13]. Yield could be increased
to 0.55% of TSP by transient expression of human IL-10 fused to
an elastin-like polypeptide combined with retention in the
endoplasmic reticulum (ER), but biological activity was not
confirmed [14]. From these experiments it was concluded that
protein instability is a major bottleneck for human IL-10
production.
We show that 3D domain swapping is an important bottleneck
for human IL-10 production in Nicotiana benthamiana. Human IL-10
multimerises extensively as was visualised in situ using GFP fusions.
Domain swapping could be prevented by engineering a stable
monomer [15] that regained biological activity through fusion to
the Fc portion of IgA, a natural dimer. Identification of this
expression bottleneck enabled us to increase yield considerably to
levels that approach the economic threshold.
Results
Yield of Mouse IL-10 is Significantly Higher Compared to
Human IL-10
To determine the maximum yield of human (h) and mouse (m)
IL-10 in a transient expression system, leaves of 5–6 weeks-old
Nicotiana benthamiana plants were agro-infiltrated. The expression
vector contained the complete native coding sequence of the
human or mouse IL-10 gene with or without a 39 tag coding for a
thrombin cleavage site, a 6xHis-tag and the ER retention sequence
KDEL (thk) (Fig. 1a). Adequate transcription of the constructs was
confirmed two and three days post infiltration (dpi) through
determination of mRNA levels by means of quantitative PCR.
Similar relative transcription levels (around 1000 transcripts of IL-
10 per b-actin transcript) were found for all four constructs on
both days (Fig. 1b). Human and mouse IL-10 yield was
determined on 1–6 dpi using a sandwich ELISA (Fig. 1c and
1d). Maximum human and mouse IL-10 yield was obtained
between 2–4 dpi. Although maximum yields were similar for
native and ER-retained IL-10, expression levels of ER-retained IL-
10 remained higher over time. Considering average yields from 2
to 5 dpi showed that ER-retained IL-10 resulted in 11 and 10-fold
more protein for human and mouse IL-10 respectively. More
striking was the observation that even though mRNA transcript
levels were comparable, mouse IL-10 yield was significantly higher
when compared to human IL-10 (P=0.043), regardless of ER-
retention (P=0.003). The average yield of mIL-10 was 19 and 17-
fold higher for secreted and ER-retained IL-10 respectively.
Retention of a protein in the ER can lead to increased yield due to
the presence of chaperones that assist protein folding and the
absence of many proteases explaining reduced degradation over
time [16]. However, as the difference in expression level between
human and mouse IL-10 was significant despite ER-retention
another factor than protein degradation supposedly influences
yield.
Human IL-10 Accumulates in Granules
To investigate the cellular fate of human and mouse IL-10 in
planta, GFP was fused C- and N-terminally to both proteins and
expression was monitored by confocal microscopy. Plants
expressing hIL-10-GFP showed fluorescent globular structures
up to 5 mm in size (Fig. 2b). These granules resembled Golgi-
bodies and were, regardless of their size, highly mobile as they
travelled along ER strands. In contrast, mIL-10-GFP showed no
or negligible signs of this phenomenon (Fig. 2c). For both proteins,
fluorescence was observed in the nuclear envelope, the ER and,
putatively, the apoplast as expected for a secretory protein (Fig. 2a).
The results of C-terminal GFP fusions harbouring the native IL-10
signal peptides, like the unfused variants, are shown. N-terminal
GFP fusions gave similar results (data not shown). Formation of
granules may be caused by aggregation of folding intermediates or
extensive multimerisation of human IL-10. Since mouse IL-10 did
not show granules as observed for human IL-10, we assumed that
formation of granules hinders yield of biologically active IL-10.
Glycosylation of IL-10 Hinders Granulation
Human and mouse IL-10 have a homology of 73% at amino
acid level. The most apparent difference between human and
mouse IL-10 during post-translational processing is the glycosyl-
ation of mouse IL-10. Both proteins have one potential N-
glycosylation site (Asn134) that is not glycosylated, while mouse
IL-10 has yet another site that is glycosylated (Asn29). As
glycosylation can stabilize a protein and influence protein folding
by mediating interaction with chaperones, it may explain the
difference in protein processing between human and mouse IL-10.
To investigate the influence of glycosylation of IL-10 on
granulation, the glycosylation site of mouse IL-10 was introduced
in human IL-10 and removed from mouse IL-10. In both cases
this was done by a single nucleotide mutation causing the serine of
human IL-10 on position 29 to change into an asparagine and vice
versa (hIL-10S29N and mIL-10N29S). Figures 3a and 3d show a
micrograph of GFP fused C-terminally to hIL-10S29N and mIL-
10N29S, respectively. Granulation of hIL-10S29N-GFP was greatly
reduced, however, never completely absent. For mIL-10N29S-GFP
granulation was induced, however, never reached the same extent
as seen for hIL-10-GFP.
To confirm the presence of a N-glycan on hIL-10S29N and the
absence on mIL-10N29S, all non-GFP fused variants were analysed
by Western blot (Fig. 3b and 3e). E. coli produced human and
mouse IL-10, hence non-glycosylated, had the same molecular
mass of 18 kDa when compared to plant-produced hIL-10 and
mIL-10N29S. The molecular weight of mIL-10 and hIL-10S29N
was, as expected upon single N-glycosylation, approximately
1.5 kDa higher. Both mIL-10 and hIL-10S29N samples also
showed a small proportion of non-glycosylated IL-10.
The effect of glycosylation on human and mouse IL-10 yield
was compared. ELISA indicated that removal of the glycosylation
of mouse IL-10 decreased yield on average 4-fold, however, this
was found not to be significant (Fig. 3c). Introducing a
glycosylation site in human IL-10 did not lead to a yield increase
(Fig. 3f), however, for hIL-10 the band intensities on Western blot
(Fig. 3b) showed that an increased amount of glycosylated hIL-10
was extracted. This discrepancy might be explained by interfer-
ence of the glycan on Asn-29 of hIL-10S29N with the binding of the
monoclonal antibodies used in ELISA.
Glycosylation does not Influence Biological Activity
The possible effects of glycosylation on the biological activity of
plant-produced human and mouse IL-10 was next assessed. The
capacity of the different IL-10 variants to reduce Tumor Necrosis
Factor-alpha (TNF-a) expression by human (THP-1) and mouse
(RAW264.7) macrophages upon stimulation by lipopolysaccharide
from E. coli was determined. Figure 4 shows the percentage
inhibition of TNF-a secretion by macrophages when compared to
the empty vector control. As expected, glycosylated as well as non-
glycosylated mouse IL-10 suppressed the secretion of pro-
inflammatory TNF-a from mouse macrophages, confirming that
glycosylation is not necessary for mouse IL-10 activity [3].
Strikingly, our data show that glycosylated human IL-10 is as
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active as its native non-glycosylated form on both human and
mouse cells. Apparently, the structure of human IL-10 is not
negatively influenced by the glycosylation event. Neither non-
glycosylated nor glycosylated mouse IL-10 was active on human
cells.
Granulation of Human IL-10 is Caused by Extensive
Multimerisation
Literature describes IL-10 to be a 3D domain swapping protein,
a term used to describe a process wherein two or more protein
chains exchange identical structural elements or ‘‘domains’’ [9,17].
Two IL-10 monomers dimerise by exchanging their E–F helices.
However, when the concentration of a potentially 3D domain
swapping protein is high, swapping of domains does not have to be
limited to two partners [18]. For example, IL-10 can provide its
A–D helices to one partner, while giving its E–F helices to another
partner. This can create a chain reaction that can, in theory,
continue until a stable form is reached. To determine if human IL-
10 granulation was triggered by extensive multimerisation, a
flexible linker was introduced between a-helices D and E of
human IL-10. This allows helices E–F of one human IL-10
molecule to fold into its own A–D a-helices, creating a stable
monomer (hIL-10mono) as designed by Josephson and co-workers
[15]. Figure 5a shows three cartoons of the expected human IL-10
Figure 1. Expression data of human and mouse IL-10 in transiently transformed Nicotiana benthamiana leaves. Use of the thk-tag gives
an increasing boost in yield for both human and mouse IL-10 from 2 days post infiltration (dpi). Strikingly, mouse IL-10 yield was significantly higher
compared to human IL-10, regardless of ER-retention. Differences in yield could not be explained by differences in mRNA transcript levels. (A)
Schematic representation of expression cassettes and vector used. Expressed genes include the native coding sequence of the human (h) or mouse
(m) IL-10 gene including signal peptide for secretion (SP) with or without a 39 tag coding for a thrombin cleavage site, a 6xHis-tag and the ER
retention sequence KDEL (thk). All expression cassettes include the 35S promoter of the Cauliflower mosaic virus with duplicated enhancer (d35S), 59
leader sequence of the Alfalfa mosaic virus RNA 4 (AlMV) and Agrobacterium tumefaciens nopaline synthase transcription terminator (Tnos). (B)
Relative transcript levels of IL-10 versus actin as determined by Q-PCR on 2 and 3 dpi (n=3, error bars indicate standard error). (C/D) Human and
mouse IL-10 yield in crude extracts (1 to 6 dpi) in mg per mg total soluble protein (TSP) as determined by ELISA (n= 3, error bars indicate standard
error).
doi:10.1371/journal.pone.0046460.g001
Figure 2. Whole mount confocal microscopy output of leaves expressing human or mouse IL-10 fused to GFP. Highly mobile globular
granules of up to 5 mm in size were observed traveling along cytoplasmic and/or ER strands for SP-hIL-10-GFP only. (A) GFP preceded by the
Arabidopsis thaliana chitinase signal peptide for secretion (SP-GFP). (B/C) The native open reading frame of human (h) and mouse (m) IL-10 including
the native signal peptide (SP) with GFP fused C-terminally.
doi:10.1371/journal.pone.0046460.g002
3D Domain Swapping of Interleukin-10 In Planta
PLOS ONE | www.plosone.org 3 October 2012 | Volume 7 | Issue 10 | e46460
Figure 3. Analysis of the effect of N-glycosylation at Asn29 on granulation. Glycosylation of IL-10 plays a role in preventing granulation. (A/
B) Whole mount confocal microscopy output of leaves expressing GFP fused C-terminally to human (h) and mouse (m) IL-10 including native signal
peptide (SP) and with introduced (S29N) or removed (N29S) glycosylation site, respectively. (C/D) Western blot analysis under reducing conditions of
plant produced (p) hIL-10 and mIL-10 with and without glycosylation site. As controls, empty vector (EV) and 50 ng recombinant (r) E. coli produced
hL-10 and mIL-10 were used. A molecular weight marker is indicated in kDa. (E/F) Yield of hIL-10 and mIL-10 with and without glycosylation site in
crude extracts 2 to 5 days post infiltration (dpi) as determined by ELISA (n= 4, error bars indicate standard error).
doi:10.1371/journal.pone.0046460.g003
Figure 4. Biological activity of human and mouse IL-10 variants on human and mouse macrophages. Plant produced (p) and
recombinant (r) E. coli produced human (h) or mouse (m) IL-10 were calibrated to contain the same amount of IL-10 as well as total soluble protein by
using the empty vector control. Human (THP-1) and mouse (RAW264.7) macrophages were then pretreated with 10 ng/ml hIL-10 or mIL-10 for
20 min and subsequently stimulated with 1 mg/ml E. coli lipopolysaccharide. Tumor Necrosis Factor-alpha (TNF-a) expression was determined by
ELISA and IL-10 activity is indicated as the percentage of inhibition of TNF-a expression as compared to the empty vector control (n= 3, error bars
indicate standard error).
doi:10.1371/journal.pone.0046460.g004
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(I) dimer, (II) monomer and (III) stable monomer conformations.
When the monomeric form of hIL-10 was fused to GFP no signs of
granulation was observed (Fig. 5b). hIL-10mono-GFP was detected
in the ER and, putatively, the apoplast. Unlike hIL-10-GFP and
mIL-10-GFP, fluorescence was also observed in the cytoplasm and
nucleoplasm. This may be indicative of partial failure of the
protein to be taken up into the secretory pathway. However, on
Western blot a band of 21 kDa, the expected size for hIL-10mono
with signal peptide, was never observed. Therefore, hIL-10mono-
GFP must be expelled from the secretory pathway and enter the
nucleoplasm by either diffusion or active transport. Active
transport into the nucleus after expulsion from the ER was
demonstrated with a secretory GFP fusion with the P-domain of
the chaperone calreticulin [19].
Western blot analysis demonstrated that hIL-10mono was indeed
present as a monomer, whereas plant and E. coli produced hIL-10
also revealed bands corresponding to dimeric (36 kDa) and
multimeric hIL-10 (Fig. 5c). In repetitive experiments a small
proportion of dimeric hIL-10mono was observed occasionally, but
never larger multimers.
Analysing average yields of hIL-10 and hIL-10mono by ELISA
revealed that the hIL-10mono protein level was significantly higher
(P=0.048) resulting in 16-fold more protein. Maximum yield
obtained with hIL-10mono was 3,2 mg IL-10/mg (0.32%) TSP at 3
dpi (Fig. 5d). However, when hIL-10mono was tested for biological
activity by assessing its ability to suppress TNF-a expression by
LPS stimulated macrophages, it appeared not to be functional
(Fig. 6a), which was expected as IL-10 receptor binding studies
suggest that the dimeric form of IL-10 confers biological activity
[20]. This experiment was repeated several times and on some
occasions slight activity of the hIL-10mono was observed, however,
always less than E. coli produced hIL-10. It appeared that the
biological activity coincided with the proportion of dimeric hIL-
10mono seen on Western blot. It is likely that the extent of
dimerisation and multimerisation of IL-10 is dependent on sample
treatment such as freeze-thaw cycles, temperature and pH of the
solution after extraction.
Biological Activity of hIL-10mono was Restored by Fusion
to Fca
To re-establish biological activity, dimerisation of hIL-10mono
was forced by fusion to the C-terminus of constant domains 2 and
3 of human immunoglobulin A2m1 (Fca). As a reference, a
construct with unmodified hIL-10 fused to Fca was also made.
Figure 6a shows the percentage inhibition of TNF-a secretion by
macrophages when compared to the empty vector control. As
mentioned before, hIL-10mono was found to have reduced
biologically activity, but by fusion to Fca we were able to restore
its biological activity (P=0.0230). Also, fusion of native hIL-10 to
Fca slightly increased biological activity, but not significant. While
the activity of the monomeric IL-10 Fca fusion had no significant
difference with E. coli or plant produced native hIL-10, a
Figure 5. Analysis of expression of a stable monomeric form of human IL-10. A stable monomeric form of human IL-10 (hIL-10mono) does
not granulate and yield increases 30-fold. (A) Three cartoons illustrating the human IL-10 (I) dimer, (II) monomer and (III) stable monomer structure, as
well as a schematic representation of the human (h) IL-10 alpha helices A–F. Helices are represented by ovals, whereby a fragment of the amino acid
sequence and the location of insertion of the small GS-linker is indicated. (B) Whole mount confocal microscopy output of GFP fused C-terminally to
hIL-10mono including native signal peptide (SP). (C) Western blot analysis under non-reducing conditions of plant produced hIL-10 and hIL-10mono. As
controls, empty vector (EV) and 50 ng recombinant (r) E. coli produced hL-10 were used. A molecular weight marker is indicated in kDa. (D) Yield of
hIL-10 and hIL-10mono in crude extracts 2 to 5 days post infiltration as determined by ELISA (n= 3, error bars indicate standard error). Average yield of
hIL-10mono was significantly higher compared to hIL-10.
doi:10.1371/journal.pone.0046460.g005
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significant difference was found with the native IL-10 Fca fusion
(P=0.0375).
Both fusion proteins showed similar accumulation patterns as
observed for the unfused variants of IL-10. However, yield of Fca-
hIL-10mono was slightly lower compared to the unfused variant on
dpi 3, but was found not to be significant (Fig. 6b). This indicates
that fusion with a stable fusion partner does not ensure increase in
yield of IL-10, as was the case with fusion to elastin-like
polypeptides [14,21].
Western blot analysis using antibodies raised against hIL-10
showed that the largest proportion had the expected size of
dimeric Fca-hIL-10 (95 kDa) for both hIL-10 and hIL-10mono
fusions, but also bands at 200 kDa and 300 kDa were observed,
which could again indicate the presence of multimers of these
fusion proteins (Fig. 6c). Using antibodies raised against IgA
revealed, in addition to all bands corresponding with the IL-10
blot, an extra band around 50 kDa (Fig. 6d). Because this band
does not appear on the IL-10 blot, it is probably a cleavage
product whereby IL-10 is removed. Specifically, a dimeric Fca
protein without hIL-10 would have an expected size of 50 kDa.
Yet, no separated IL-10, expected at 18 or 36 kDa for monomeric
and dimeric IL-10 respectively, was seen and must therefore be
completely degraded.
Discussion
Here we show that extensive multimerisation of human IL-10 is
the most important factor limiting yield and not protein instability.
Human IL-10 has previously been expressed in plants [12,14,21–
23]. The highest yield of 0.55% of TSP was obtained by transient
expression of human IL-10 fused to an elastin-like polypeptide
while retained in the ER. It was suggested that retention in the
protein friendly environment of the ER protects the protein
against degradation and that elastin-like polypeptides might
prevent aspecific aggregation by association with chaperones
[12,14]. These data suggested a role for protein instability or
inefficient post-translational processing as a limiting factor for
production of human IL-10. Protein instability as a bottleneck for
production of IL-10 would not be surprising, as cytokines are
known for their short half-life in vivo.
Figure 6. Analysis of biological activity and expression of human IL-10 and human IL-10mono fused to Fca. Forced dimerization of
human IL-10mono restores biological activity. (A) Bioactivity assay of hIL-10mono and Fca-hIL-10 fusion proteins on mouse macrophages (RAW267.4).
Plant produced (p) and recombinant (r) E. coli produced hIL-10 were calibrated to contain the same amount of IL-10 as well as total soluble protein by
using the empty vector control. Cells were then pretreated with 50 ng/ml hIL-10 for 20 min and subsequently stimulated with 1 mg/ml E. coli
lipopolysaccharide. Tumor Necrosis Factor-alpha (TNF-a) expression was determined by ELISA and IL-10 activity is indicated as the percentage of
inhibition of TNF-a expression as compared to the empty vector control (n= 4, error bars indicate standard error). Significant difference (P,0.05)
between samples is indicated with an asterisk, where biological activity of hIL-10mono was significantly different to all other samples. (B) Yield of
human (h) IL-10 in crude extracts 2 to 5 days post infiltration as determined by ELISA (n= 3, error bars indicate standard error). (C/D) Western blot
analysis under non-reducing conditions of plant produced (p) Fca-hIL10 and Fca-hIL-10mono using an antibody raised against human IL-10 and
human IgA for visualization, respectively. As controls, empty vector (EV), 50 ng recombinant (r) E. coli produced hIL-10 and 10 ng purified hIgA were
used. A molecular weight marker is indicated in kDa.
doi:10.1371/journal.pone.0046460.g006
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When we studied the cellular fate of human and mouse IL-10
in planta using GFP fusions, we revealed that human IL-10
accumulates in granules, while mouse IL-10 does not. The most
evident difference between human and mouse IL-10 is the N-
glycosylation of mouse IL-10. Both proteins have one potential
N-glycosylation site (Asn134) that is not glycosylated, while
mouse IL-10 has yet another site that is glycosylated (Asn29).
Removal of the Asn29 glycosylation site resulted in increased
granulation of mouse IL-10, whereas introduction of this
glycosylation site in human IL-10 prevented granulation to a
large extent. As glycosylation can aid in protein folding and
stabilization, we hypothesized that the granules were in fact very
large aggregates, potentially compartmentalised as a cell
protective mechanism.
Aggregation can be due to protein instability and/or misfold-
ing resulting in random hydrophobic patch interaction or, in the
case of IL-10, due to extensive multimerisation. Literature
describes IL-10 to be a 3D domain swapping protein, a term
used to describe a process wherein two or more protein chains
exchange identical structural elements or ‘‘domains’’ [9,17]. IL-
10 monomers form biologically active dimers by exchanging their
E–F helices. However, at high concentrations of IL-10 it would
be possible that the domain swapping of IL-10 is not limited to
two partners and causes a chain reaction that, in theory, could go
on unlimited until a stable form is reached. To determine
whether human IL-10 granulation was due to protein instability
or due to 3D domain swapping, the behaviour of a previously
developed stable monomeric form of human IL-10 [15] was
studied in planta. This stable monomeric form of human IL-10 has
a short glycine-serine (GS)-linker between helices D and E
allowing the helices E–F to fold back into its own hydrophobic
core created by the A–D helices (human IL-10mono). No
granulation was observed when human IL-10mono was fused
with GFP. Multimeric or high molecular weight bands of human
IL-10mono were also not detected by Western blot. Furthermore,
yield was increased on average 16-fold by this minor modification
of the human IL-10 protein. This expression level was
comparable to the highest yield obtained for human IL-10 so
far, however, without retention in the ER or fusion with a stable
protein partner. Taken together, we show that not protein
instability, but extensive multimerisation of human IL-10, due to
its intrinsic 3D domain swapping characteristic, is the major
limiting factor for yield.
Bennett and colleagues introduced the term 3D domain
swapping [17] and up to date almost 300 proteins have been
reported with 3D domain swapping ability [24]. Besides IL-10,
the cytokines Granulocyte Macrophage Colony-Stimulating
Factor (GM-CSF), Interleukin-5 (IL-5) and Interfernon-beta
(IFN-b) are also described as 3D domain swapping proteins [9]
and have been heterologously expressed in several platforms.
Upon expression in E. coli the formation of inclusion bodies were
described for these four cytokines [25–28]. Although formation of
inclusion bodies could be indicative of multimerisation, they are a
relatively common feature when expressing eukaryotic proteins in
E. coli due to aggregation of folding intermediates. However, in
the case of IFN-b and IL-5, experiments also demonstrated the
need for slow removal of denaturing agents to prevent
aggregation to reoccur after solubilisation of inclusion bodies
[25,26]. To our knowledge, IL-5 has not been produced in plants
before and expression of human IFN-b in lettuce leaves resulted
in poor yields [29]. On the other hand, many research groups
have produced human GM-CSF in planta. Interestingly, human
GM-CSF secreted by a tobacco cell culture could be stabilized in
the growth medium by addition of bovine serum albumin, gelatin
or salt, all methods that could inhibit protein aggregation [30,31].
Next to that, when produced in rice seeds a morphological
change in both plant protein body type I and the ER were
observed together with high molecular weight variants of human
GM-CSF from 50 to 120 kDa [32,33]. Menassa and colleagues
also described a 200 kDa weight variant of human IL-10 when
expressed stably in a tobacco species [12]. For both human IL-10
and human GM-CSF yield from rice seeds was relatively high
compared to the leaf-based and cell culture systems, however,
extraction from rice seeds was only efficient using reducing agents
[23,34]. Unfortunately, use of reducing agents during extraction
would increase production costs again, as the protein would need
to be chemically refolded. There are many indications that
extensive multimerisation has also hampered the production of
other 3D domain swapping cytokines, and may represent a more
common mechanism affecting yield than thus far anticipated. In
addition, it is unclear how 3D domain swapping influences
biopharmaceutical proteins during formulation, storage and
administration.
Although we could increase the yield of human IL-10
significantly by expression of a stable monomeric form of IL-10,
this form was not biologically active, as determined by its ability to
reduce TNF-a secretion by lipopolysaccharide-stimulated macro-
phages. Even though human IL-10mono has all the receptor
binding sites, the affinity may be reduced. Josephson and co-
workers did show biological activity of human IL-10mono based on
its ability to induce proliferation of a B cell line, however, a 10-fold
higher amount of human IL-10mono was needed to obtain the
same effect as recombinant human IL-10 [15]. Stable monomeric
forms of IL-5 were also created and shown to have reduced
receptor affinity. Nevertheless, they did show biological activity
with concentration dependence close to that of the wild type [35].
Such stabilized biologically active forms of 3D domain swapping
cytokines will ensure that the protein stays in its biologically active
conformation, which may have great benefit for formulation and
administration to patients.
To mimic the natural dimerization of IL-10 while still
preventing multimerisation, human IL-10mono was fused to the
naturally dimerising Fc portion of IgA2m1 (Fca), which restored
the ability to suppress TNF-a in stimulated macrophages. As well
as ensuring dimeric conformation, it is likely that fusion with Fca
increases in vivo half-live of IL-10, which could be beneficial for
efficacy. Our construct is comparable to that of mouse IL-10 fused
to the N-terminus of a non-cytolytic version of the Fc portion of
mouse IgG2a, which was shown to be functional in vivo with a
prolonged efficacy due to its increased circulating half-life [36].
However, an increased half-life of IL-10 could also lead to
unwanted systemic side effects, such as a compromised immune
system. By using complete antibodies it may be possible to
circumvent these side effects. Through the antigen binding
capacity of an antibody with IL-10 fused C-terminally, specific
cells or tissues can be targeted enabling IL-10 therapy for a variety
of diseases, as was already demonstrated by Schwager and co-
workers [37]. In disease therapy, use of a human fusion protein is
desired to limit the chance of an immune response against the
therapeutic agent. Also, in inflammatory disease therapy the use of
IgA may be preferred over other antibody isotypes, as it does not
activate the classical complement pathway. Thus, a stable
molecule that ensures a biologically active conformation and
targeting, such as Fca-IL-10, may be a more suitable format for
medical applications and may prove effective in therapy of
inflammatory diseases.
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Experimental Procedures
Construction of Expression Cassettes and Vector
The complete native open reading frames (ORF) of human and
mouse IL-10 were amplified from the MegaManTM Human
Transcriptome cDNA library (Stratagene) and FirstChoiceTM
PCR-Ready Mouse Spleen cDNA library (Ambion), respectively,
using oligonucleotides indicated in Table 1. Sense and antisense
oligonucleotides included NcoI and KpnI restriction sequences,
respectively, for subsequent cloning steps. Introduction of the NcoI
restriction site resulted in the addition of two extra amino acids to
the signal peptide at the N-terminus. All oligonucleotides used for
subsequent reamplification, mutagenesis and insertion can be
found in Table 1.
To create hIL-10thk and mIL-10thk, both hIL-10 and mIL-10
ORFs were reamplified, resulting in the removal of the stop codon
and replacement of the KpnI by a NotI restrictrion site. The thk
coding DNA fragment could be added in frame. To remove and
introduce the glycosylation site of mouse and human IL-10
respectively, the QuickChange XL kit (Stratagene) was used. For
insertion of the 6 amino acid glycine-serine spacer overlap
extension PCR was performed in combination with original hIL-
10 oligonucleotides.
The DNA fragment encoding the enhanced green fluorescent
protein (eGFP) was reamplified from gateway vector pK7FWG2
[38]. Constructs with eGFP fused C-terminally to IL-10 were
composed of the IL-10 fragments ending with NotI (as described
for the h/mIL-10thk constructs) the ‘‘NotI-NcoI’’ oligo and the
eGFP fragment.
The constant domains 2 and 3 of human immunoglobulin
A2m1 heavy chain including a N-terminal IgA signal peptide and
a C-terminal linker sequence was synthetically constructed by
GeneArt and fused N-terminally to reamplified SpeI-hIL-10 and
SpeI-hIL-10mono fragments.
All constructs were placed under the control of the 35S
promoter of the Cauliflower mosaic virus with duplicated enhancer
(d35S) and the Agrobacterium tumefaciens nopaline synthase tran-
scription terminator (Tnos). A 59 leader sequence of the Alfalfa
mosaic virus RNA 4 (AlMV) was included between the promoter
and construct to boost translation. All elements were present in
pRAP35 (or pUCAP35S [39]) from which expression cassettes
were digested with AscI and PacI and ligated into a modified
version of the expression vector pMDC32 [40], renamed pHYG.
The pHYG vector resulted upon removal of the Gateway
recombination sequences by digestion with EcoRI and HindIII
and replacement with a DNA fragment (oligos ‘‘pHYG adaptor’’)
including AscI and PacI restriction sites for insertion of the
expression cassettes.
All construct sequences were confirmed by sequencing (Base-
Clear) at the expression vector stage. The expression vectors were
subsequently transformed to Agrobacterium tumefaciens strain
MOG101 for plant expression.
Agrobacterium tumefaciens Transient Transformation
Assay
Agrobacterium tumefaciens clones were cultured overnight (o/n) at
28uC in LB medium (10g/l pepton140, 5g/l yeast extract, 10g/l
NaCl with pH 7.0) containing 50 mg/ml kanamycin and 20 mg/ml
rifampicin. The optical density (OD) of the o/n cultures was
measured at 600 nm and used to inoculate 50 ml of LB medium
containing 200 mM acetosyringone and 50 mg/ml kanamycin with
x ml of culture using the following formula: x = 80000/(1028*OD).
OD was measured again after 16 hours and the bacterial cultures
were centrifuged for 15 min at 28006g. The bacteria were
resuspended in MMA infiltration medium (20g/l sucrose, 5g/l
MS-salts, 1.95g/l MES, pH5.6) containing 200 mM acetosyrin-
gone till an OD of 1 was reached. After 1–2 hours incubation at
room temperature, the two youngest fully expanded leaves of 5–6
weeks old Nicotiana benthamiana plants were infiltrated completely.
Infiltration was performed by injecting the Agrobacterium suspension
into a Nicotiana benthamiana leaf at the abaxial side using a 1 ml
syringe. Infiltrated plants were maintained in a controlled
greenhouse compartment (UNIFARM, Wageningen) and infil-
trated leaves were harvested at selected time points.
Total Soluble Protein Extraction
Leaves were immediately snap-frozen upon harvesting, homog-
enized in liquid nitrogen and stored at 220uC until use.
Homogenized plant material was ground in ice-cold extraction
buffer (50 mM phosphate-buffered saline (PBS) pH=7.4,
100 mM NaCl, 10 mM ethylenediaminetetraacetic acid (EDTA),
0.1% v/v Tween-20, 2% w/v immobilized polyvinylpolypyrroli-
done (PVPP)) using 2 ml/g fresh weight. Crude extract was
clarified by centrifugation at 16.0006g for 5 min at 4uC and
supernatant was directly used in an ELISA and BCA protein
assay. For western blotting and biological activity assays, above-
mentioned protein extraction would be followed by desalting using
a G25 Sephadex column and filter sterilization (0.22 mm;
Millipore Corporation).
Quantification of Human and Mouse IL-10 mRNA Levels
mRNA was isolated from homogenized plant material using the
RNAeasy Plant Mini Kit (Qiagen) according to suppliers protocol.
A Turbo DNaseI (Ambion) treatment was included to remove any
residual DNA. cDNA was synthesised using the SuperScriptHIII
First-Strand Synthesis System (invitrogen) according to suppliers
protocol. Samples were analysed by quantitative PCR in triplo
using ABsolute SYBR Green Fluorescein mix (Thermo Scientific).
Nicotiana benthamiana b-actin was used as a reference gene.
Oligonucleotides used can be found in Table 1. Relative transcript
levels of IL-10 versus actin were determined by the Pfaffl method
[41].
Quantification of Human and Mouse IL-10 Protein Levels
IL-10 protein concentration in crude plant extract was
determined by ELISA. Human and mouse IL-10 ELISA Ready-
SET-Go!H kits (eBioscience) were used according to suppliers
protocol using the model 680 plate reader (BioRad) to measure the
OD at 450 nm with correction filter of 690 nm. For sample
comparison the total soluble protein (TSP) concentration was
determined by the BCA method (Pierce) according to supplier’s
protocol using bovine serum albumin (BSA) as a standard.
Protein Analysis by Western Blot
Soluble plant proteins were separated under reducing or non-
reducing conditions by SDS-PAGE on a NuPAGEH 12% Bis-Tris
gel (Invitrogen). Recombinant E. coli produced human or mouse
IL-10 (R&D Systems) or IgA1 (Invivogen) was used as a control.
Proteins were transferred to an InvitrolonTM PVDF membrane
(Invitrogen) by semi-dry blotting procedure. Thereafter the
membrane was blocked in PBST-BL (PBS containing 0.1% v/v
Tween-20 and 5% w/v non-fat dry milk powder) for 1 hour at
room temperature, followed by overnight incubation with hIL-10
specific goat polyclonal antibody (R&D systems), mIL-10 specific
rat monoclonal antibody (BioLegend) or IgA specific HRP
conjugated goat polyclonal antibody (Sigma) in PBST at 4uC.
The membrane was washed 5 times with 5 min intervals in PBST.
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For h/mIL-10 specific western blots the procedure was continued
with a 1 hour incubation at room temperature with HRP
conjugated secondary antibodies (Jackson ImmunoResearch) in
PBST and washed again as described before. Finally, the
SuperSignal West Femto substrate (Pierce) was used to detect
HRP-conjugated antibodies.
Confocal Microscopy
Plants were agro-infiltrated with expression cassettes encoding
C-terminal fusions of GFP to human and mouse IL-10 as
described previously. Leaves were taken from the plant and small
sections were examined from the abaxial side using a Zeiss
LSM510 confocal laser-scanning microscope in combination with
an argon ion laser supplying a 488 nm wavelength.
Biological Activity Assay
The monocyte THP-1 and monocyte/macrophage
RAW264.7 cell lines were purchased from the American Type
Culture Collection and cells were maintained at 37uC with 5%
CO2. THP-1 cells were cultured in RPMI-1640 medium
containing containing 4 mM L-glutamine, 25 mM HEPES and
supplemented with 10% fetal calf serum, 50 U/ml penicillin
and 50 mg/ml streptomycin. THP-1 monocytes were differen-
tiated into macrophages for 4 days using 30 ng/ml PMA at a
density of 36105 cells/ml in 96 well plates. Cells were allowed
to rest for 2–3 days in medium without PMA prior to
bioassays. RAW264.7 cells were cultured in DMEM contain-
ing 4 mM L-glutamine, 25 mM HEPES and supplemented
with 10% newborn calf serum, 50 U/ml penicillin and 50
mg/ml streptomycin. Cells were sub-cultured every 2–3 days,
whereby the cells were harvested by gently disrupting the
monolayer with a cell scraper. For cell-based assays cells were
seeded in 96 well plates at a density of 56104 cells/well and
allowed to rest overnight. For bioassays cells were pre-treated
with 10–50 ng/ml plant produced or recombinant E. coli
produced human or mouse IL-10 (R&D Systems) in plant
extract for 20 min, and subsequently stimulated with 1 mg/ml
of lipopolysaccharide (Sigma). After overnight incubation
supernatants were analysed with the mouse TNF-a ELISA
Ready-Set-Go! Kit (eBioscience) according to the supplier’s
protocol.
Data Analysis
All data shown in the figures indicate the average of at least
three biological replicates (n) that were determined by at least three
technical replicates. In the figure legends n is indicated and error
bars indicate the standard error. Significant differences between
samples were calculated using the student’s t-test and regarded as
significant when P,0.05. Significant differences in expression
levels between constructs were calculated by using the whole data
set from dpi 2 to 5 and are indicated in the main text as well as the
figure legends. When comparing biological activity between
proteins significant differences are indicated in the figure by
asterisks.
Acknowledgments
We would like to thank Kevin van der Eijken, Francisco Marques, Bart
Nijland, Debbie van Raaij, Sonja Warmerdam and Edgar Wills for their
input in the practical work of this paper.
Table 1. Oligonucleotides used for construct re-amplification, mutagenesis and insertion.
Gene
fragment Function 5’ –.3’ Sense oligonucleotides 5’ –.3’ Antisense oligonucleotides
hIL-10 Isolation hIL-10 NcoI/KpnI ccatgggcATGCACAGCTCAGCACTGCTCT cggtaccTCAGTTTCGTATCTTCATTGTCA
mIL-10 Isolation mIL-10 NcoI/KpnI ccatggccATGCCTGGCTCAGCACTGCTAT ccggtaccTTAGCTTTTCATTTTGATCATC
pHYG adaptor MCS including AscI/PacI aattcggcgcgcctacgcgtaaggacgagc
tctgaggtacctctagattaattaaa
agcttttaattaatctagaggtacctcagagctcgtccttacgcgtaggcgcgccg
hIL-10-NotI Removal stop codon,
addition NotI
ccatgggcATGCACAGCTCAGCACTGCTCT ggcggccgcGTTTCGTATCTTCATTGTCATG
mIL-10-NotI Removal stop codon,
addition NotI
ccatggccATGCCTGGCTCAGCACTGCTAT ggcggccgcGCTTTTCATTTTGATCATCATG




eGFP Isolation GFP NcoI/KpnI gtcgacggatccATGGTGAGCAAGGGCG
AGGAGCTGTTC
aggtaccTTAGCTCATGACTGACTTGTAGAGCTCGTCCATGCCGAGAG







hIL-10mono Insertion GGGSGG-linker AAACggtggcggatctgggggtAAGAGCAAGGC
CGTGGAGCAGGTGAA
CTTacccccagatccgccaccGTTTTCACAGGGAAGAAATCGATGA
SpeI-hIL-10 Removal SP, addition SpeI accatggactagtAGCCCAGGCCAGGGCAC cggtaccTCAGTTTCGTATCTTCATTGTCA
h/m IL-10 Q-PCR analysis ATGATCCAGTTTTACCTGG AGAAATCGATGACAGCG
Nb b-actin Q-PCR analysis CCAGGTATTGCCGATAGAATG GAGGGAAGCCAAGATAGAGC
Native sequences in capitals, added/mutated sequences in small and restriction sites are underlined. h; human, IL-10; interleukin-10, MCS; multiple cloning site, m;
mouse, Nb; Nicotiana benthamiana, SP; signal peptide for secretion, thk; thrombin-6xHIS-KDEL tag.
doi:10.1371/journal.pone.0046460.t001
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